QSAM begins patient enrolment for bone cancer therapy trial
QSAM Biosciences has commenced subject enrolment for its Phase I clinical trial of its therapy CycloSam (Samarium-153 DOTMP) to treat bone cancer, after activating its…
Patent Analytics
Trends in IP Protection— Clinical (Last 20 Years)
Heavy IP Protected Regions — Clinical (Last 20 Years)
Top Players Protecting their IP — Clinical (Last 20 Years)
Top Themes Protected by IP - Clinical (Last 20 Years)
All markets data shared in the dashboard is copyright of GlobalData PLC and is subject to the GlobalData Terms & Conditions. Content in the dashboard should not be viewed as a recommendation and should not be relied upon to make investment decisions. We make every effort to ensure our content is accurate and to correct mistakes as soon as possible. If you spot an error please email editorialenquiries@globaldata.com. Further information about our editorial standards and complaints procedure is available here. GlobalData is not responsible for the use of any content outside the scope of the GlobalData Terms & Conditions.
Latest News
View More
Revelation Biosciences begins Phase IIb trial of H3N2 influenza therapy
Revelation Biosciences has commenced a Phase IIb study of its intranasal drop solution, REVTx-99, in healthy individuals to prevent H3N2 influenza (influenza A). The solution…
Sobi and Selecta Biosciences complete enrolment for gout therapy trial
Swedish Orphan Biovitrum (Sobi) and Selecta Biosciences have completed the enrolment of participants for the DISSOLVE I study to assess…
GreenLight and IAVI partner for Phase I trial of Covid-19 vaccine in Africa
GreenLight Biosciences has collaborated with non-profit scientific research organisation International AIDS Vaccine Initiative (IAVI) for a Covid-19 vaccine trial in…
Longeveron to explore cell-based therapy in trial of older and frail subjects
Longeveron has signed a sponsored clinical research agreement with Japan’s National Center for Geriatrics and Gerontology (NCGG) and Juntendo University…
Axial Therapeutics begins dosing in Phase IIb autism therapy trial
Axial Therapeutics has dosed the first participants in an international Phase IIb clinical trial of a gut-targeted molecular therapy, AB-2004,…
Company A-Z
View More
VaLea Clinical Trials
Patient-Centric Services for In-Home or Alternate-Site Clinical Trials Settings
